🎉 M&A multiples are live!
Check it out!

Vaxcell-Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vaxcell-Bio and similar public comparables like CSL, Imugene, and Prescient Therapeutics.

Vaxcell-Bio Overview

About Vaxcell-Bio

Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.


Founded

2010

HQ

South Korea
Employees

n/a

Website

vaxcell-bio.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$104M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Vaxcell-Bio Financials

Vaxcell-Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Vaxcell-Bio achieved revenue of $1.3M and an EBITDA of -$6.1M.

Vaxcell-Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Vaxcell-Bio valuation multiples based on analyst estimates

Vaxcell-Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $9K $1.3M XXX XXX XXX
Gross Profit n/a $5K XXX XXX XXX
Gross Margin NaN% 0% XXX XXX XXX
EBITDA -$6.7M -$6.1M XXX XXX XXX
EBITDA Margin -71635% -470% XXX XXX XXX
Net Profit -$4.7M -$7.0M XXX XXX XXX
Net Margin -49733% -541% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Vaxcell-Bio Stock Performance

As of April 15, 2025, Vaxcell-Bio's stock price is KRW 8090 (or $6).

Vaxcell-Bio has current market cap of KRW 186B (or $127M), and EV of KRW 152B (or $104M).

See Vaxcell-Bio trading valuation data

Vaxcell-Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$104M $127M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Vaxcell-Bio Valuation Multiples

As of April 15, 2025, Vaxcell-Bio has market cap of $127M and EV of $104M.

Vaxcell-Bio's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Vaxcell-Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Vaxcell-Bio and 10K+ public comps

Vaxcell-Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $104M XXX XXX XXX
EV/Revenue 80.0x XXX XXX XXX
EV/EBITDA -17.0x XXX XXX XXX
P/E -17.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -10.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vaxcell-Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Vaxcell-Bio Valuation Multiples

Vaxcell-Bio's NTM/LTM revenue growth is n/a

Vaxcell-Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Vaxcell-Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Vaxcell-Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Vaxcell-Bio and other 10K+ public comps

Vaxcell-Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 13737% XXX XXX XXX XXX
EBITDA Margin -470% XXX XXX XXX XXX
EBITDA Growth -9% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 108% XXX XXX XXX XXX
G&A Expenses to Revenue 77% XXX XXX XXX XXX
R&D Expenses to Revenue 318% XXX XXX XXX XXX
Opex to Revenue 811% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Vaxcell-Bio Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Vaxcell-Bio M&A and Investment Activity

Vaxcell-Bio acquired  XXX companies to date.

Last acquisition by Vaxcell-Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Vaxcell-Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Vaxcell-Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Vaxcell-Bio

When was Vaxcell-Bio founded? Vaxcell-Bio was founded in 2010.
Where is Vaxcell-Bio headquartered? Vaxcell-Bio is headquartered in South Korea.
Who is the CEO of Vaxcell-Bio? Vaxcell-Bio's CEO is Mr. Je-jung Lee.
Is Vaxcell-Bio publicy listed? Yes, Vaxcell-Bio is a public company listed on KRX.
What is the stock symbol of Vaxcell-Bio? Vaxcell-Bio trades under 323990 ticker.
When did Vaxcell-Bio go public? Vaxcell-Bio went public in 2020.
Who are competitors of Vaxcell-Bio? Similar companies to Vaxcell-Bio include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of Vaxcell-Bio? Vaxcell-Bio's current market cap is $127M
What is the current revenue growth of Vaxcell-Bio? Vaxcell-Bio revenue growth between 2023 and 2024 was 13737%.
Is Vaxcell-Bio profitable? Yes, Vaxcell-Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.